Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

New pages

More actions
New pages
Show bots | Show redirects | Hide reviewed edits
(newest | oldest) View ( | ) (20 | 50 | 100 | 250 | 500)

22 May 2026

20 May 2026

  • 03:2603:26, 20 May 2026 Adult ADHD Self-Report Scale (hist | edit) [7,009 bytes] MDElliottMD (talk | contribs) (Create encyclopedic page for the ASRS-v1.1 (Adult ADHD Self-Report Scale): development under the WHO (Kessler, Harvard; Adler, NYU), structure (18-item checklist + 6-item Screener), threshold scoring, validation, the DSM-5 update, wiki use as the validated companion to AMAAS, and the NYU/Harvard licensing + mandatory attribution notice. Citations Kessler 2005 PMID 15841682, Kessler 2007 PMID 17623385, Ustun 2017 PMID 28384801, all NCBI-eutils-verified. Describes the instrument; reproduces no...)

19 May 2026

  • 06:2206:22, 19 May 2026 THCV (hist | edit) [1,405 bytes] MDElliottMD (talk | contribs) (Create Tetrahydrocannabivarin (THCV) medicine stub: minor phytocannabinoid, propyl analogue of THC, biphasic CB1 activity (low-dose neutral antagonist, high-dose partial agonist), investigational interest in appetite suppression and type 2 diabetes. Cites Russo 2011 (PMID 21749363).)
  • 06:2206:22, 19 May 2026 CBG (hist | edit) [1,502 bytes] MDElliottMD (talk | contribs) (Create Cannabigerol (CBG) medicine stub: minor phytocannabinoid, biosynthetic precursor from CBGA to THCA/CBDA/CBCA, non-psychoactive, multiple non-CB pharmacology targets. Cites Russo 2011 (PMID 21749363).)
  • 06:2206:22, 19 May 2026 CBN (hist | edit) [1,144 bytes] MDElliottMD (talk | contribs) (Create Cannabinol (CBN) medicine stub: minor phytocannabinoid, THC oxidation product, weak CB1 partial agonist, popularly framed as a sleep cannabinoid with sparse controlled evidence. Cites Russo 2011 entourage-effect review (PMID 21749363).)
  • 03:1603:16, 19 May 2026 Lixisenatide (hist | edit) [807 bytes] MDElliottMD (talk | contribs) (Create Lixisenatide stub: short-acting GLP-1 receptor agonist (Adlyxin / Lyxumia, FDA 2016, withdrawn from US market 2023). Closes last redlink in Category:GLP-1 receptor agonists.)

18 May 2026

(newest | oldest) View ( | ) (20 | 50 | 100 | 250 | 500)